Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

GlaxoSmithKline says data supports Cervarix two-dose schedule for young girls
Yahoo/Fly on the Wall
Monday, November 4, 2013 - 9:58am
tags:
GSK, Cervarix, vaccines, HPV, cervical cancer
Pain drug developer Zogenix narrows 3rd quarter loss as expenses fall
Yahoo/AP
Monday, November 4, 2013 - 9:56am
tags:
earnings, Zogenix
Pfizer's Not Losing Its Kingpin Status
Yahoo/TheStreet.com
Monday, November 4, 2013 - 9:52am
tags:
Pfizer, Zoetis
Merck experimental vaccine shows promise in cancer trial
Yahoo/Reuters
Monday, November 4, 2013 - 9:52am
tags:
vaccines, Merck, V503, Gardasil, HPV
Merck: Why Oncology Smells Like Money
Seeking Alpha
Monday, November 4, 2013 - 9:49am
tags:
Merck, oncology, Roche, Bristol-Myers Squibb, MK-3475, melanoma
Bristol-Myers Vs. Abbvie In Potential Humira Rivalry
Seeking Alpha
Monday, November 4, 2013 - 9:47am
tags:
AbbVie, Humira, Bristol-Myers Squibb, clazakizumab
Vertex Failure Shows Biotech Is Not Immune To Big Pharma-Type Layoffs
Forbes
Monday, November 4, 2013 - 9:26am
tags:
Vertex Pharmaceuticals, layoffs
Achillion presents preclinical profile of HCV drug candidate
Yahoo/Fly on the Wall
Monday, November 4, 2013 - 9:19am
tags:
hepatitis C, Achillion, ACH-3422
6 Charts Explain An Ugly October for Biotech Stocks
TheStreet.com
Monday, November 4, 2013 - 9:18am
tags:
biotech, Catalyst Pharmaceutical Partners, Acadia, Celldex, Biocryst
Tecfidera Succeeds in Protecting Biogen's MS Market Share From Novartis' Gilenya
Motley Fool
Sunday, November 3, 2013 - 12:12pm
tags:
Gilenya, Novartis, MS, multiple sclerosis, Biogen Idec, Tecfidera
Is Abbott Labs Destined for Greatness?
Motley Fool
Sunday, November 3, 2013 - 12:11pm
tags:
Abbott Laboratories
These 2 Businesses Could Boost Sanofi's Top Line
Motley Fool
Sunday, November 3, 2013 - 12:10pm
tags:
Sanofi, diabetes, orphan drugs
New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting
Yahoo/BusinessWire
Sunday, November 3, 2013 - 12:08pm
tags:
Enanta Pharmaceuticals, ABT-450, ABT-267, hepatitis, hepatitis C
Gilead Sciences and Johnson & Johnson Push Vertex Out of Hepatitis C Race
Motley Fool
Sunday, November 3, 2013 - 12:06pm
tags:
Gilead Sciences, JNJ, Vertex Pharmaceuticals, hepatitis, hepatitis B
5 Short-Term Catalysts Make Galena Biopharma A Long-Term Buy
Seeking Alpha
Sunday, November 3, 2013 - 12:03pm
tags:
Galena Biopharma
Dr.Reddy’s wins trademark case against Reddy Pharma
The Hindu, India
Saturday, November 2, 2013 - 12:08pm
tags:
Dr Reddy's, lawsuits
Manufacturing Sold Separately? Dendreon's Plan B.
Motley Fool
Saturday, November 2, 2013 - 12:06pm
tags:
Dendreon
1 Big Pharma Giant on the Verge of a Turnaround
Motley Fool
Saturday, November 2, 2013 - 11:58am
tags:
Sanofi
Bristol seeks Japan approval of all-oral hepatitis C treatment
Yahoo/Reuters
Saturday, November 2, 2013 - 11:56am
tags:
Bristol-Myers Squibb, daclatasvir, asunaprevir, hepatitis C, hepatitis
Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Yahoo/BusinessWire
Saturday, November 2, 2013 - 11:40am
tags:
MK-5172, MK-8742, hepatitis C, hepatitis

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.